Podcasts about IV

On today's episode, Dr. Mark Costes is joined by Dr. Brandon Chapek, a general dentist turned surgical powerhouse who's built a thriving, high-production practice centered around wisdom tooth extractions and IV sedation. Brandon shares his unique path from growing up on a farm to walking away from oral surgery residency, opting instead for a fellowship and a business model that prioritizes autonomy and lifestyle balance.  With over $3.5 million in personal production, Brandon dives into how he streamlined surgery protocols, scaled with PPO patients, and created an in-house system that now runs with surgical efficiency. He also introduces his new book, Wisdom Tooth Surgery for the General Dentist, packed with step-by-step guidance for GPs who want to add this lucrative skillset to their practice. Whether you're looking to stop referring out, expand your clinical scope, or just work smarter, this is a conversation full of actionable takeaways. Be sure to check out the full episode from the Dentalpreneur Podcast! EPISODE RESOURCES brandonchapek@gmail.com https://www.truedentalsuccess.com Dental Success Network Subscribe to The Dentalpreneur Podcast

In this episode, we take calls about: some Would You Rather questions that ROCK the pod, a person who was subjected to crying during a hookup, and a caller who keeps sleeping with their tattoo artist whoopsie! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 4:16 Would You Rather 25:21 Crying About Grandma 46:09 Slept With My Tattoo Artist 1:02:01 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices

We talk Stacey's Get your drip on company!

Is it possible to transform 20 years of addiction into a life of purpose, clarity, and helping others?David Price can tell you. After 20 years of IV heroin addiction, he made the choice that changed everything. Walking into his first 12-step meeting, he broke down crying—not understanding why. Now he knows it was divine intervention. David shares his journey from sleeping on his grandmother's pull-out couch with no car and massive debt to building an ultra-successful insurance business. "A lot of my friends didn't make it," he reminds us. His philosophy? Master one small, achievable goal. Then another. The gift of recovery? Falling asleep in minutes with a clear conscience. Why share now? "To help somebody." His story proves transformation is possible—one day at a time.David Price is the CEO and Founder of The Price Group IMO, one of the fastest-growing organizations in financial services. His story is proof that anyone can change their life. After overcoming addiction and rebuilding from rock bottom in 2013, David earned his insurance license in 2018 and built a simple system that helps everyday people—single moms, career changers, or anyone looking for extra income—create a living from home. Within just 36 months he became a millionaire, and his organization has now surpassed $10 million in its first year.Today, David's mission is to mentor people who want more freedom, flexibility, and financial independence, giving them the tools and guidance to succeed regardless of their background or experience.About The Show: The Life in Transition, hosted by Art Blanchford focuses on making the most of the changes we're given every week. Art has been through hundreds of transitions in his life. Many have been difficult, but all have led to a depth and richness he could never have imagined. On the podcast Art explores how to create more love and joy in life, no matter what transitions we go through. Art is married to his lifelong partner, a proud father of three and a long-time adventurer and global business executive. He is the founder and leader of the Midlife Transition Mastery Community. Learn more about the MLTM Community here: www.lifeintransition.online.In This Episode: (00:00) The Most Impactful Transition(08:45) The Tipping Point to Sobriety(16:53) Finding the Right Recovery Path(21:27) MidLife Transition Mastery Ad(24:53) Building Success After Rock Bottom(38:35) The Power of Small, Achievable Goals(43:33) Transition Mastery Coaching Ad(45:20) Tools for Lasting Transformation(57:03) Connecting With David PriceLike, subscribe, and send us your comments and feedback.Resources:Website: www.tpglife.comInstagram: https://www.instagram.com/davidpriceofficial/Facebook: https://web.facebook.com/DavidPriceOfficialLinkedIn: https://www.linkedin.com/in/davidpriceofficial/Tiktok: https://www.tiktok.com/@davidpriceofficialYoutube: https://www.youtube.com/@DavidPriceOfficialTwitter: https://x.com/IAMDavidPriceEmail Art BlanchfordLife in Transition WebsiteLife in Transition on IGLife in Transition on FBJoin Our Community: https://www.lifeintransition.online/My new book PURPOSEFUL LIVING is out now. Order it now: https://www.amazon.com/PURPOSEFUL-LIVING-Wisdom-Coming-Complex/dp/1963913922Explore our website https://lifeintransitionpodcast.com/ for more in-depth information and resources, and to download the 8-step guide to mastering mid-life transitions.The views and opinions expressed on the Life In Transition podcast are solely those of the author and guests and should not be attributed to any other individual or entity. This podcast is an independent production of Life In Transition Podcast, and the podcast production is an original work of the author. All rights of ownership and reproduction are retained—copyright 2025.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Como Ana, hay mucha gente en España...Ana tiene 48 años y ha sufrido cuatro ictus, así que va en silla de rudas y depende de que la ayuden los demás. Como Ana, el 85% de los que sobreviven a un accidente cerebrovascular, necesitan soporte. De hecho, el 60% de los familiares de estas personas tienen que abandonar sus trabajos para dedicarse a ellos en cuerpo y alma.Y ahora, prepárense, porque vamos a sacar pecho.Se llama Robopedics, y es una empresa española. 100% española. Ha desarrollado un robot para ayudarles a volver a caminar. Un exoesqueleto que se acopla fácilmente en las piernas, en la cadera, y los levanta. Es un 60% más ligero y un 80% más barato que otras soluciones. Y lo diseñó Iván. Y saben por qué lo ideó. Porque su padre sufrió un ictus.El año que viene podría estar ya en el mercado, pero, de momento, ya lo están usando en algunos hospitales. Y Ana, por ejemplo, podrá entrar en su cocina. Y cortarse las uñas.Y todo eso, por la idea ...

El 7 de diciembre de 2017, Iván va a pasar la tarde a casa de un amigo, aunque no es habitual que salga de su piso porque tiene la salud delicada y no quiere ponerse enfermo. Vuelve sobre las 18:00h., pero no se da cuenta de que no lo hace solo: alguien ha estado vigilando sus movimientos y se ha colado en su garaje detrás de él.Más información en el blog: https://criminopatia.com/148-ivan-castro¡Hazte fan de Criminopatía! Tendrás dos nuevos episodios exclusivos cada mes, todos los meses del año: http://criminopatia.com/fansY síguenos en redes en @criminopatia.

Isla Vista's bluffs have been the scene of several tragic events. can be dangerous. for KCSB's Emerson Good spoke with Captain Scott Safechuck, public information officer with SB County Fire, about asoaked - and, when earth is saturated like this - it's the most dangerous time to be on, around or below the bluffs. To learn more about how well IV's bluffs fared in the storm - and if there are safety concerns heading into this next round of rain, I spoke with Scott Safechuck, public information officer for Santa Barbara County Fire. later in our conversation, Captain Safechuck will talk about Isla Vista's latest cliff fall rescue - which took place last weekend.

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversan con Hernán Larraín y Ximena Jara sobre cómo enfrentan los candidatos presidenciales la campaña de cara a segunda vuelta.

Siloé cierran 2025 con "Si Te Pones de Mi Parte", una canción nostálgica y épica pero luminosa y con un piano precioso que recuerda a "Clocks", de Coldplay. Escuchamos la versión que Iván Ferreiro ha grabado de Turnedo, veinte años después de su publicación, a Monstruo Laberinto con la hipnótica "Humo Humano", que bebe de Justice y el regreso de Extrogenuinas con "Bea Vapea". IVÁN FERREIRO - TurnedoREPION - Cerrar los ojosMONSTRUO LABERINTO - Humo HumanoVELOCITY GIRL - Your Silent FacePIPIOLAS - Soy Una EstrellaVEINTIUNO - Pide Un Deseo Por MíSILOÉ - Si Te Pones de Mi ParteVIVA SUECIA - Dolor y GloriaELYELLA, LORI MEYERS - Tenemos La RespuestaDIRT BUYER - Get To ChooseCELIA ES CELÍACA - Las Siete Menos DiezEXTROGENUINAS - Bea VapeaCHIQUITA MOVIDA - Fotos FelicesELEM - La SalvaciónCHARLI XCX_Chains of LoveAMAARAE - Starkilla ft. Bree Runway & StarkillersEscuchar audio

Dr. Edmund Tsui interviews Dr. Brian C. Toy on his retrospective cohort study which shows that oral doxycycline clinical and serologic outcomes are comparable to IV penicillin for syphilitic uveitis, published in Ophthalmology. From "Outpatient Oral Doxycycline versus Intravenous Penicillin for Syphilitic Uveitis." Outpatient Oral Doxycycline versus Intravenous Penicillin for Syphilitic Uveitis. Bao, Yicheng K. et al. Ophthalmology, Volume 132, Issue 12, 1457 - 1459.

The Earth is All That Lasts by Mark Lee Gardner w/Jesan Sorrells------Music: Peer Gynt Suite no. 1, Op. 46 - IV. In the Hall Of The Mountain King - Czech National Orchestra---Opening and closing themes composed by Brian Sanyshyn of Brian Sanyshyn Music.---Pick up your copy of 12 Rules for Leaders: The Foundation of Intentional Leadership NOW on AMAZON!Check out the 2022 Leadership Lessons From the Great Books podcast reading list!--- ★ Support this podcast on Patreon ★ Subscribe to the Leadership Lessons From The Great Books Podcast: https://bit.ly/LLFTGBSubscribeCheck out HSCT Publishing at: https://www.hsctpublishing.com/.Check out LeadingKeys at: https://www.leadingkeys.com/Check out Leadership ToolBox at: https://leadershiptoolbox.us/Contact HSCT for more information at 1-833-216-8296 to schedule a full DEMO of LeadingKeys with one of our team members.---Leadership ToolBox website: https://leadershiptoolbox.us/.Leadership ToolBox LinkedIn: https://www.linkedin.com/company/ldrshptlbx/.Leadership ToolBox YouTube: https://www.youtube.com/@leadershiptoolbox/videosLeadership ToolBox Twitter: https://twitter.com/ldrshptlbx.Leadership ToolBox IG: https://www.instagram.com/leadershiptoolboxus/.Leadership ToolBox FB: https://www.facebook.com/

En el invierno de 1950, las fuerzas de la ONU, lideradas por Estados Unidos, avanzaban confiadas hacia el norte de Corea cuando se encontraron con un enemigo inesperado: el contraataque chino en el embalse de Chosín. Los marines estadounidenses quedaron rodeados por divisiones chinas superiores en número pero mal armadas. La retirada que siguió fue una de las más duras de la guerra moderna. Tiene el dudoso honor de ser la más larga de una unidad de marines de los EE.UU. En este episodio analizamos el colapso del frente, la estrategia china y cómo Chosín cambió para siempre el curso de la Guerra de Corea. Te lo cuentan Iván Giménez y Dani CarAn. Casus Belli Podcast pertenece a 🏭 Factoría Casus Belli. Casus Belli Podcast forma parte de 📀 Ivoox Originals. 📚 Zeppelin Books (Digital) y 📚 DCA Editor (Físico) http://zeppelinbooks.com son sellos editoriales de la 🏭 Factoría Casus Belli. Estamos en: 🆕 WhatsApp https://bit.ly/CasusBelliWhatsApp 👉 X/Twitter https://twitter.com/CasusBelliPod 👉 Facebook https://www.facebook.com/CasusBelliPodcast 👉 Instagram estamos https://www.instagram.com/casusbellipodcast 👉 Telegram Canal https://t.me/casusbellipodcast 👉 Telegram Grupo de Chat https://t.me/casusbellipod 📺 YouTube https://bit.ly/casusbelliyoutube 👉 TikTok https://www.tiktok.com/@casusbelli10 👉 https://podcastcasusbelli.com 👨💻Nuestro chat del canal es https://t.me/casusbellipod ⚛️ El logotipo de Casus Belli Podcasdt y el resto de la Factoría Casus Belli están diseñados por Publicidad Fabián publicidadfabian@yahoo.es 🎵 La música incluida en el programa es Ready for the war de Marc Corominas Pujadó bajo licencia CC. https://creativecommons.org/licenses/by-nd/3.0/ El resto de música es bajo licencia privada de Epidemic Music, Jamendo Music o SGAE SGAE RRDD/4/1074/1012 de Ivoox. 🎭Las opiniones expresadas en este programa de pódcast, son de exclusiva responsabilidad de quienes las trasmiten. Que cada palo aguante su vela. 📧¿Quieres contarnos algo? También puedes escribirnos a casus.belli.pod@gmail.com ¿Quieres anunciarte en este podcast, patrocinar un episodio o una serie? Hazlo a través de 👉 https://www.advoices.com/casus-belli-podcast-historia Si te ha gustado, y crees que nos lo merecemos, nos sirve mucho que nos des un like, ya que nos da mucha visibilidad. Muchas gracias por escucharnos, y hasta la próxima. ¿Quieres anunciarte en este podcast? Hazlo con advoices.com/podcast/ivoox/391278 Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversan con Allan Álvarez y Cristián Valenzuela sobre los más de dos millones de votos obtenidos por Franco Parisi y cómo se dividirán de cara a la segunda vuelta.

Descubrimos la IV edición de los Premios Talento Emergente “La torre de Babel”, impulsados por Fundación Caja Rural de Aragón y Aragón Radio. Unos galardones que celebran la creatividad de los jóvenes aragoneses menores de 35 años en seis categorías: Audiovisual, Creación Literaria, Artes Plásticas, Música, Empresas e Iniciativas Culturales y Artes Escénicas. La presentación de esta edición corre a cargo de Laura Prada, directora de la Fundación Caja Rural de Aragón, y Ana Segura, jefa de Contenidos de Aragón Radio, quienes explican la importancia de apoyar y visibilizar el talento joven en la comunidad.

Why watch Jaws II and IV? Carter explains. Also, retro gaming stores in China Town, bad time at The Special Noodle, drawing Frankenstein, Luke's legacy, finding the devil in the bacon, moving friends into another house, your questions and emails and a crap ton more. Hosted on Acast. See acast.com/privacy for more information.

Send us a textOne of the episodes recorded in the summer of 2025, Dustin and I dig deep into his inspirations, songwriting process, and he shares a lot of wise words, in addition to chatting about their latest album. This episode is great for any musician/songwriter, or fan's of blues-rock!Fronted by ferocious guitarist/singer/songwriter Dustin Douglas, The Electric Gentlemen—rounded out by drummer Tommy Smallcomb and bassist Matt Gabriel—are known to deliver a heavy dose of swagger, groove, and rock 'n' roll attitude both on stage and in the studio.IV—the fourth studio endeavor from Dustin Douglas & The Electric Gentlemen—is a raw, unapologetic, Blues-Rock Master course.  It is a powerhouse album drenched in whiskey-soaked riffs and soaring Rock n' Roll vocals that once again display Douglas' meteoric rise as one of the heaviest hitters in the Blues-Rock world.  The album was recorded at Eight Days a Week Studios in Northumberland, PA by Paul Smith (Badlees), who engineered and co-produced the album with Douglas.  It was mixed and mastered by Nick Coyle (Lifer, Drama Club, Death Valley Dreams).  IV is the follow-up album to DDEG's 2023 release, BLACK LEATHER BLUES.“IV is an album inspired by letting go of any musical chains,” says Dustin Douglas. “I had no intention of following any genre restraints or restrictions.”Creator/Host: Tammy TakaishiAudio Engineer: Tammy Takaishi/Alex Repetti Visit the Self-Care Institute at https://www.selfcareinstitute.com/ Support the showVisit www.creativepeacemeal.com to leave a review, fan voicemail, and more!Insta @creative_peacemeal_podcastFB @creativepeacemealpodRedbubble CPPodcast.redbubble.comCreative Peacemeal READING list here Donate to AhHa!Broadway here! Donate to New Normal Rep here! Interested in the Self-Care Institute with Dr. Ami Kunimura? Click here Interested in Corrie Legge's content planner? Click here to order!

Is mold the hidden culprit behind your fatigue, brain fog, and stubborn “diagnoses” that never resolve? Get the real 101 on mycotoxins, mold exposure, and what actually works.Renowned clinician Andrew Campbell, M.D. with 35+ years in integrative medicine, 100+ publications, and global lectures from Oxford to national TV joins Dr. Shivani Gupta in the Fusionary Health Podcast to decode mold illness. He explains how indoor leaks seed toxic spores, why urine tests mislead, and how mycotoxins masquerade as autoimmune, neurological, and hormone problems especially in perimenopause and menopause.Dr. Campbell outlines a data-backed healing roadmap: precise antibody blood testing, an effective antifungal, eight targeted supplements, and an anti-inflammatory, low-histamine diet—plus when IV vitamin C helps, why curcumin is clutch, and what to avoid (binders, glutathione with gliotoxin). Perfect for anyone seeking functional, evidence-based answers and a clear roadmap to real recovery.✨ Key Highlights:• Mold 101: how leaks create toxic spores you can't see• Testing Truths: urine vs. blood and why antibodies tell the real story• Mycotoxins & Misdiagnosis: mimicking MS, Lyme, autoimmune & hormone issues• Treatment Pillars: antifungal + 8 targeted supplements + low-histamine diet• Curcumin Power: anti-inflammatory & detox benefits + IV vitamin C support• Myths to Avoid: binders hype and glutathione with gliotoxinWhy You Should Watch:If you're battling brain fog, chronic fatigue, or hormone chaos, this episode gives you a clear plan to heal. Learn how to identify mold exposure, choose the right tests, and apply evidence-based treatment pillars while avoiding detox myths. Reclaim your focus, balance, and vitality naturally.

I was prepared for the physical challenges of my first HYROX event. What I didn't expect was for it to reveal just how much emotional weight I'd been carrying. Somewhere between the training, the illness, the IV drips, and the intensity of race day, HYROX pulled up years of grief, loneliness, self-protection, and the quiet ache of doing life solo for far too long. The sudden 14-pound weight spike in just two weeks became the wake-up call I couldn't ignore — the physical proof of everything I'd been holding in. This event didn't just test my body. It cracked open everything I've been avoiding. It forced me to feel the pain I've suppressed… maybe even used fitness to outrun. And it made me face the ways I've kept people at a distance because it felt safer than risking disappointment. This is the real story of how HYROX became less about the competition and more about healing, trauma patterns, and emotional clarity. If you've ever pushed down your pain until it showed up in your body… If you've ever kept people at arm's length because disappointment hurts more than loneliness… If you've ever been confronted with the truth you've been avoiding... This episode is going to hit home. Sponsored by Hydralive

Why watch Jaws II and IV? Carter explains. Also, retro gaming stores in China Town, bad time at The Special Noodle, drawing Frankenstein, Luke's legacy, finding the devil in the bacon, moving friends into another house, your questions and emails and a crap ton more. Hosted on Acast. See acast.com/privacy for more information.

Sobre los ejes económicos que los comandos de Jeannette Jara y José Antonio Kast están delineando de cara a la segunda vuelta; y la crisis que se instaló en el bloque de derecha tras la elección del domingo, Iván Valenzuela conversó con las editoras Marily Lüders y Paula Valenzuela en un nuevo Rat Pack de Mesa Central.

Goedenmorgen! Today, travel medicine specialists Drs. Paul Pottinger & Chris Sanford answer your travel health questions, including:IV hydration spas are everwhere... are they safe?Do I need to be immunized against diphtheria?Prickly Heat and Disney Vasculitis–What's the difference?What is hepatitis E?Rotten Air BNB with nice hosts… ethics of an honest review?WTF is up with chikungunya on Long Island?How to avoid–and treat–low back pain on long trips?How can I tell if I'm fit enough for an upcoming trip?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please visit our website: germandworm.com where you can find all our content and send us your questions and travel health anecdotes. Or, just send us an email: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

LEVITICUS 5 — THE LAW OF ASHAM (TRESPASS)“Accountability, Restoration, and the Fear of Yahuah”Teachers: Kerry & Karen BattleAhava ~ Love AssemblyToday's class dives into Leviticus 5 — The Law of Asham (Trespass), where Yahuah reveals how hidden guilt, broken oaths, and neglected responsibility fracture covenant order.This is not ritual.This is Yahuah's justice system.Leviticus 5 exposes the five forms of trespass that demand confession and restitution:1. Withholding truth (Lev 5:1)2. Touching death unknowingly (Lev 5:2–3)3. Rash or impulsive oaths (Lev 5:4–5)4. Misusing what is qodesh (Lev 5:15–16)5. Sin done in ignorance (Lev 5:17–19)Each connects directly to Exodus 21–23, the backbone of Yahuah's justice architecture:Life is sacredProperty is protectedTestimony is bindingOaths are covenantalRestitution is requiredNegligence equals guiltThe vulnerable must be defendedLeviticus 5 is the continuation of covenant justice — not a separate ritual.

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversan con Isabel Plá y Tatiana Klima sobre la sorpresiva votación que dejó a Franco Parisi en tercer lugar y los 14 diputados electos del Partido de la Gente.

In this week's episode, we talk about: a guy who is asked to mask around his partner's friends, a see through bikini prank gone WRONG, a couple of workers pretending to be fired when customers complain too much, a listener who is stuck between a chapel and Chappell, and the LEAST banal poop story we've ever come across. Erika also tells us the tales of her Sims journey of late! This Episode is Brought to You By: Chewy! Go to ⁠Chewy.com/ChewyClaus to make a wish and help donate 5 meals to pets in need! Article! Go to ⁠Article.com/Judgies⁠ for $50 off your first purchase of $100 or more! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 4:13 BF Needing To Mask 13:33 See Through Bikini 25:45 Pretending To Be Fired 35:48 Break 37:12 CJ: Sims Drama 54:14 LS Sound 57:19 LS Story 1:07:40 Least Banal Poop 1:23:45 Outro Story Links: Is it ableist to expect my autistic partner to behave appropriately around others? Aita for wearing the “joke” bikini my friend got me? AITA for pretending to get fired when customers get a temper with me? I did not wash my rear end until I was 19, and it's beyond embarrassing Learn more about your ad choices. Visit megaphone.fm/adchoices

Show notes at pharmacyjoe.com/episode1079. In this episode, I'll discuss the bioavailability of methadone. The post 1079: Time to rethink the conversion of oral methadone to IV? appeared first on Pharmacy Joe.

In this "Just the Babes" episode, we break down new research on melatonin, from cardiovascular implications to ideal sourcing and dosing. We explore how circadian rhythms shape bone health and revisit the Daylight Saving Time debate. The conversation moves into nutrition and environmental exposures, covering red meat and cancer risk, glyphosate's epigenetic effects, and emerging links between EMFs and Alzheimer's. We wrap up with practical EMF-protection strategies, a look at regenerative therapies including peptides, IV exosomes, and shockwave treatment, and our experience with Prenuvo (the full-body MRI scan).SHOW NOTES:0:39 Welcome to the podcast!2:45 Melatonin & cardiovascular risk6:42 Melatonin sourcing & dosing9:28 Circadian-regulated bone health12:35 Daylight Saving debate14:09 Red Meat & cancer16:36 Infinite Epigenetics & Glyphosate20:22 EMFs & Alzheimers22:20 EMF-Protection tips25:18 Peptides for healing31:10 IV Exosomes34:27 Shockwave Therapy38:39 Prenuvo MRI Scan46:51 “Human” YouTube feature47:38 Thanks for tuning in!RESOURCES:Think Melatonin is Safe?Circadian Rhythm & Bone HealthRed Meat & Brain HealthEMF's & AlzheimersInfinite Epigenetics  - code: BIOHACKERBABES for 30% offCrowd CowU.S. Wellness MeatsHAVN EMF-safe clothing - code: BIOHACKERBABESDefender Shield - code: BIOHACKERBABESEllieMD PeptidesPrenuvo MRI Scan - $300 off: email us at biohackerbabes@gmail.comRecellebrate IV ExosomesHuman Show with Sierra ClarkSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Series: GratefulWeek 1 Title: I Am GratefulScripture: Philippians 4:4–7; Philippians 2:28; Philippians 4:11–13Big Idea:Gratitude is what makes peace possible.I. The Context of GratitudePaul writes Philippians not from comfort but from a Roman prison cell.He's chained to uncertainty yet overflowing with joy, peace, and thanksgiving.Gratitude isn't tied to circumstances—it's anchored in the presence of God.Even here, I'm grateful.II. Fix Your Focus“Rejoice in the Lord always” — a command, not a suggestion.Joy is not denial—it's direction. You choose where to aim your attention.Where your attention goes, your emotions follow.When anxiety rises, fix your focus on God's presence, not your problems.Philippians 2:28 shows that Paul himself experienced anxiety—so it's not sin, it's human.“You can't stop anxious thoughts from showing up, but you can decide where they go.”III. Gratitude Changes Our PhysiologyPhilippians 4:5 — “Let your gentleness be evident to all. The Lord is near.”Gentleness = calm presence born from gratitude.Gratitude grounds us in God's nearness rather than our fear.The practice of presence transforms anxiety into awareness of peace.IV. Gratitude is the Pathway to PeaceThanksgiving is in the prayer, not just after the answer.Gratitude invites supernatural peace that surpasses understanding.“The peace of God will guard your hearts and minds in Christ Jesus.”Peace doesn't mean everything makes sense; it means your heart is guarded in the chaos.Testimonies: marriages saved, friendships restored, hope renewed—all through gratitude.V. Learning the PracticeGratitude is not fake optimism—it's honest faith.“God, I hate the hard times. But I'm grateful You're still with me in them.”Philippians 4:11–13 — Paul learned contentment in every season.We don't stumble into gratitude; we practice it until it shapes us.Fix your focus. Change your physiology. Let peace guard your heart.

Dr. Ted Traylor shares a message about praying for and witnessing to the lost based on Romans 10:1-15. A message from November 16, 2025. 00:00 - Introduction 08:39 - I. Praying for Heart Change 10:52 - II. Praying for Verbal Confession 13:30 - III. Praying for All to Be Saved 16:33 - IV. Praying for Preachers to Be Sent Visit olivebaptist.org for more information.

Cultural Differences and Government with Maria Paula Correa Maria Paula Correa serves as Chief Relationship Officer at Libra Group, overseeing global partnerships with governments and key stakeholders. Based in Miami and Bogotá, she is part of the Group's Leadership Team. She plays a pivotal role in establishing connections that bridge cultural differences and align government priorities across international markets. Her focus is on creating trust-based relationships that drive cooperation and sustainable growth. Between 2018 and 2022, Maria was Chief of Cabinet to the President of Colombia, working under President Iván Duque Márquez. In this position, she directed interinstitutional coordination, international relations, and strategic communications for the national government. Before that, she was Senior Director of Strategic Engagement at Concordia, promoting dialogue on global partnerships and how cultural differences and government influence policy and collaboration. Earlier, she worked as Consul at the Colombian Consulate in New York and as Advisor to the Chief of Staff during President Álvaro Uribe's administration, strengthening Colombia's diplomatic relations abroad. Maria holds an MPA from Columbia University's School of International and Public Affairs and a B.A. in Law with a Political Science concentration from Universidad de Los Andes in Colombia. She also completed diplomas in Political Communications from Universidad Javeriana and Public Management and Administrative Institutions from Universidad de Los Andes. Her background demonstrates a deep commitment to diplomacy, public service, and leadership. Through her work, she consistently emphasizes how cultural differences and government dynamics shape global decision-making and cooperation. In addition to her executive responsibilities, Maria serves on the Board of Directors of Casa Editorial El Tiempo, Colombia's largest media organization, where she contributes to strengthening informed dialogue and international understanding. Her tips to become more culturally competent are: Pay attention to detail. Don't underestimate cultural intelligence. Always respond, even though they might not like the response. Listen before you interpret and respond. You need to have contacts. This is usually more valuable than what you know. Build cultural curiosity into your life. Want to avoid the most common mistakes when working internationally? Read this article. Cultural Differences and Government with Maria Paula Correa More stories and culture can be found here. Culture Matters The Culture Matters Podcast on International Business & Management Podcast Build your Cultural Competence, listen to interesting stories, learn about the cultural pitfalls and how to avoid them, and get the Global perspective here at the Culture Matters podcast on International Business. We help you understand Cultural Diversity better by interviewing real people with real experiences. Every episode there is an interview with a prominent guest, who will tell his or her story and share international experiences. Helping you develop your cultural competence. Welcome to this culture podcast and management podcast. To Subscribe to this Management Podcast, Click here. The Culture Matters Culture Podcast. Available on iTunes and Stitcher Radio Click here to get the podcast on Spotify Talk to your Amazon Alexa and listen to the Podcast Listen directly on Amazon If you have a minute, please leave me an honest rating and review on iTunes by clicking here. It will help the visibility and the ranking of this culture podcast on iTunes immensely! A BIG THANK YOU! Enjoy this FREE culture podcast! Music: Song title - Bensound.com More Ways of Listening: Get a Taste of How Chris Presents, Watch his TEDx Talk     Name Email Address Phone Number Message 14 + 13 = Send Call Direct: +32476524957   European Office (Paris) Whatsapp: +32476524957   The Americas (USA; Atlanta, GA; también en Español):  +1 678 301 8369 Book Chris Smit as a Speaker If you're looking for an Engaging, Exciting, and Interactive speaker on the subject of Intercultural Management & Awareness you came to the right place. Chris has spoken at hundreds of events and to thousands of people on the subject of Cultural Diversity & Cultural Competence. This is What Others Say About Chris: “Very Interactive and Engaging” “In little time he knew how to get the audience inspired and connected to his story” “His ability to make large groups of participants quickly and adequately aware of the huge impact of cultural differences is excellent” “Chris is a dedicated and inspirational professional” In addition, his presentations can cover specific topics cultural topics, or generally on Cultural differences. Presentations can vary anywhere from 20 minutes to 2 hours and are given worldwide. Book Chris now by simply sending an email. Click here to do so. Read more about what Chris can do for you. Percentage of People Rating a Presentation as Excellent 86% 86% Rating the Presentation as Practical 89% 89% Applicability of Chris' presentation 90% 90% About Peter van der Lende Peter has joined forces with Culture Matters. Because he has years and years of international business development experience joining forces therefore only seemed logical. Being born and raised in the Netherlands, he has lived in more than 9 countries of which most were in Latin America. He currently lives in Atlanta, Georgia (USA) with his family. You can find out more at https://expand360.com/ Or find out what Peter can do for you here.

I. The Holy Spirit enlightens the eyes of our hearts, in answer to prayer, vv17-18 II. We need the Spirit to enlighten the eyes of our hearts in the hope of God's calling, v18a III. We need the Spirit to enlighten the eyes of our hearts in the riches of God's inheritance, v18b IV. We need the Spirit to enlighten the eyes of our hearts in the greatness of God's power, vv19-20

AABP Executive Director Dr. Fred Gingrich is joined by Dr. Geoffrey Smith, dairy technical services veterinarian with Zoetis. Calf scours remains a significant cause of morbidity and mortality in beef and dairy calves. Smith reviews his presentation from the 2025 AABP conference in Omaha, Neb. and AABP members can view that presentation on the CE portal by going to this page.  Understanding the pathophysiology of neonatal scours can help veterinarians and producers understand the treatment goals. Calves with scours typically have a metabolic acidosis with hyponatremia, hypokalemia, hypoglycemia and dehydration. It is important to replace the sodium to rehydrate the calf. Smith reviews the IV fluid therapy options including lactated ringers, isotonic sodium bicarbonate, hypertonic saline solution, and hypertonic sodium bicarbonate. Calculating the base deficit can be done with bloodwork but can also be estimated with an estimate of 20 mEq/L in a down calf. Smith also reviews some guidelines for a good oral electrolyte solution which includes 90-130 mEq/L of sodium, glycine for an energy source and to help sodium be absorbed from the gut, an alkalinizing agent such as sodium bicarbonate or sodium acetate, a strong ion difference (sodium plus potassium minus chloride) of at least 60 which is an indication of the fluid's ability to alkalinize the calf.  We also review some of the questions asked at the conference. As we prepare for winter and the next calving season, this episode will help veterinarians and your clients prepare for treating calf scours when our prevention efforts fail. 

Para analizar el día después de la elección presidencial y parlamentaria; además de los ánimos al interior de la candidatura oficialista, el estratega de la campaña de Jeannette Jara, Darío Quiroga, conversó este lunes con Angélica Bulnes e Iván Valenzuela, en una nueva edición del Rat Pack de Mesa Central.

Este lunes, en Columnistas de Mesa Central, Iván Valenzuela conversó con María José Naudon y Patricio Fernández, quienes analizaron la jornada electoral, destacando que el ascenso de Franco Parisi revela una profunda crisis en las lógicas de poder tradicionales y obliga a repensar el significado de los votos de izquierda y derecha.

Most people think the path to wealth is income, and today's guest, Morgan Keim, thought that, too. But after building food-tech startups for a decade, he realized financial freedom required more than a high-paying job; it required a fundamental shift. Join host Iván Watanabe and his former high school classmate, Morgan Keim, as they explore … Read More Read More

From horse tranquilizer to mental health treatment — what's the real story about ketamine? Nick Pell breaks it down on Skeptical Sunday!Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we're joined by writer and researcher Nick Pell!Full show notes and resources can be found here: jordanharbinger.com/1241On This Week's Skeptical Sunday:Ketamine therapy shows promise for treatment-resistant depression, PTSD, and chronic pain, but it's serious medicine requiring proper medical supervision, not a recreational escape or wellness trend.Clinical ketamine treatment involves IV administration with precise dosing, vital monitoring, and trained medical attendants — drastically different from recreational use that can cause severe bladder damage and other complications.The rise of telehealth ketamine clinics and mail-order treatments represents a concerning trend — proper vetting requires full psych evaluations, bloodwork, and screening by legitimate medical professionals, not vague promises.Recreational ketamine use carries significant addiction potential and health risks, particularly bladder damage from chronic high doses — clinical settings minimize these dangers through controlled administration.If you're considering ketamine therapy, start with a therapist and real medical doctor. Look for evidence-based treatment with proper intake procedures, not spa-like "optimization centers" making grandiose claims.Connect with Jordan on Twitter, Instagram, and YouTube. If you have something you'd like us to tackle here on Skeptical Sunday, drop Jordan a line at jordan@jordanharbinger.com and let him know!And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors: The Cybersecurity Tapes: Listen here: thecybersecuritytapes.comBiOptimizers: 25% off November 23rd to December 3rd: bioptimizers.com/jordan, code JORDANHomes.com: Find your home: homes.comShopify: 3 months @ $1/month (select plans): shopify.com/jordanApretude: Learn more: Apretude.com or call 1-888-240-0340See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we chat with Karen Bystedt, AKA,  KB, a celebrated artist and CEO of thelostwarhols and @kbhealthandbeauty2024. Her work has been featured at The Warhol Museum and the Astrup Fearley Museum. KB shares her journey as a sought-after photographer known for her striking celebrity portraits that blend pop culture with personal narratives. With a Master's in Fine Arts, she explores themes of identity and culture, often reflecting her connection to Andy Warhol through unique stylistic approaches. She discusses her inspiring recovery from stage IV  colon cancer and her philosophy of embracing life's challenges. KB also shares her deep connection to spirituality and self-affirmation, living life her way through art and her new collection. We wrap up with details about the "LOOK UP" movement event in Times Square on November 27th, where over 40 creatives will gather. Special thanks to Rachel Vancelette for her incredible support in making this happenYou can connect with Karen Bystedt on Instagram @karenbystedt or check out her website www.karenbystedt.com

In this episode of BioTalk, CEO Gerard Eldering explains how Perfusion Medical is addressing a problem that trauma physicians and military medics have been struggling with for decades: capillary compression.  Perfusion Medical is developing a drug aimed at treating hemorrhagic shock and other ischemic conditions. PM‑208 is a novel IV therapeutic designed to restore capillary blood flow, resolve ischemia, and protect vital organs. The team has advanced this work with $19 million in Department of Defense funding. He describes the scale of the unmet need, why PM‑208 is both organ- and disease‑agnostic, and how its simple formulation and strong safety profile position it for broad medical use. Eldering also reflects on the company's path through the BioHealth Capital Region Crab Trap Competition. After a second‑place finish a few years earlier, Perfusion Medical returned to the stage and won the 2025 competition. He shares what that experience has meant for the team and why building the company in the BioHealth Capital Region—particularly from a Virginia base—has been a strategic advantage. The conversation moves through the role of early federal funding and programs like SBIR/STTR in de‑risking breakthrough therapies, and how university research partnerships have strengthened PM‑208's development. Eldering highlights how public‑private collaboration has shaped the company's progress and made it possible to push a complex medical solution toward patients more quickly.   Editing and post-production work for this episode was provided by The Podcast Consultant - https://thepodcastconsultant.com/0   About Gerard Eldering Gerard Eldering is the CEO of Perfusion Medical and a nationally recognized expert in technology transfer and venture formation. Since becoming an entrepreneur in 2007, he has helped launch more than a dozen startups, raised more than $15 million in seed funding, and led the turnaround and sale of a technology consulting firm. Before founding Perfusion Medical, he built and led The MITRE Corporation's Technology Transfer Office. Eldering is a U.S. Air Force veteran who served as a helicopter pilot and instructor. He holds a B.A. in Physics, an M.B.A., and is a registered patent agent.

Бог – Ревнитель-1 / God is a Jealous One-1 Даниил 5:1-12Даниил 9I. Вызов Богу / Challenge to God    А. Безумная беспечность / Reckless Carelessness B. Безрассудное решение / Rash Decision C. Религиозное кощунство / Religious BlasphemyII. Божье откровение / God's RevelationIII. Реакция царя / The King's ReactionIV. Совет царицы / The Queen's Advice

En una edición especial y conjunta de Radios 13, en el Rat Pack, Iván Valenzuela conversó con las editoras Angélica Bulnes, Paula Comandari y Andrea Vial López sobre los hechos que están marcando la agenda.

Captive thoughts I. Weapons of our warfare II. Strongholds pulled down III. Arguments cast down IV. Thoughts into captivity V. Disobedience punished

Do the many clinical trials into high-dose vitamin C prove it can actually treat the common cold and cancer, rather than just boost the immune system? Why is there ongoing scepticism? Why are multifactorial chronic diseases so hard to study in clinical trials? What is the right dosage to get the best results from vitamin C?In this episode we have the often misunderstood topic of Vitamin C as an antioxidant to get clear on, particular the high-dose approach and particularly delivered intravenously. Despite a very clear consensus that Vitamin C is a great booster to immune function, research that shows that it helps fight the common cold or flu have been dismissed by doctors and medical researchers; as well as claims that higher doses can increase its efficacy. Other claims that Vitamin C can help fight cardio-vascular disease and even cancer have been with even greater scepticism. So what exactly can vitamin C do to assist our immune function to fight disease, and why is there so much confusion about the answer given the high quantity of clinical trials data?Fortunately today's guest has exactly the right skill set and research knowledge to separate the science from the here-say, medical doctor and orthomolecular medicine researcher, Dr. Richard Z Cheng. Dr. Cheng has a PhD in biochemistry and molecular biology; he's served as a doctor in the US military; he has consulted for the National Cancer Institute, and presented at the National Institute of Health (NIH); he has conducted clinical trials; He is the editor in Chief of the Orthmolecular Medicine New Service; He is also a fellow of the American Academy of Anti- Aging medicine; and has run anti-aging and regenerative medicine clinics in both China and the US for over 20 years.What we discuss:00:00 Intro05:15 Most animals produce Vitamin C in the body, but not primates.06:00 Oxidation & Redox: Giving or receiving an electron.11:00 After reducing oxidation the body recycles it back into vitamin C.14:00 Teamwork: sharing electrons between nutrients and vitamins.18:20 Conventional consensus: good for prevention but not treatment.21:00 Over 80K papers on Vit C on Pub Med!21:30 Linus Pauling Intravenous Vitamin C for cancer and heart disease.27:00 Shortening of common cold and lowering of symptoms - Harri Hemila.29:00 Low dose studies dilute the data on the efficacy of the high dose studies.31:00 Intravenous treatment allows much higher doses safely.33:00 Differences in absorption between IV and oral application.35:20 Pro-oxidant effect only possible at IV high dose.36:30 IV clinical trials.39:20 Cytokine storm cascades in acute respiratory distress.44:00 High Dose IV Vitamin C saved lives in China during Covid 19.50:00 Attacks following Richard's NIH presentation on Vitamin C during covid.57:00 Cardio vascular disease - Vit. C research history.01:01:00 Collagen Synthesis for vascular walls & Vitamin C deficiency.01:07:20 Is the taboo for life style medicine lifting?01:09:30 Issues of gold standard RCT trials not working for multifactorial integrative interventions.01:16:00 Recommendations for preventative use of Vitamin C for listeners. References:E Cameron & Linus Pauling - 'Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer', 1976E.T. Creagan, 'Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer', 1979Harri Hemilä - over 200 meta-analyses and clinical trialsPing Chen et al. 'Pharmacokinetic Evaluation of Intravenous Vitamin C'Richard Z Cheng, ‘Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?'KU Cancer Center researchers announce study of high-dose intravenous vitamin C to treat muscle-invasive bladder cancer, 2024National Cancer Institute overview of IV Vitamin C cancer research.

Escucha el podcast del programa Basketball con Iván Mieses a través de CDN Radio, en Santo Domingo, República Dominicana correspondiente al sábado 15-noviembre-2025.

Two weeks ago, Gaslit Nation pointed out that Vance is grooming the Christian nationalist movement to accept him as Trump's replacement. Turns out Vance knew–they all knew–that the Epstein paper trail was radioactive. The House released explosive Epstein documents that confirm what Gaslit Nation listeners already knew: the real story is not what's been revealed, but what's still being buried. We will continue to unpack this story as it develops, including the Kremlin connection as Epstein tried to advise Russia when it came to Trump.  For now, the Big Takeaways:  The emails released came from the Epstein estate. So what might Trump's DOJ and FBI be sitting on?: Photos, videos, and unredacted FBI and CIA files. Miami Herald reporter Julie K. Brown, whose investigations helped bring down Epstein and Ghislaine Maxwell, and the resignation of Trump labor secretary Alex Acosta who gave Epstein a "sweetheart deal" and was rewarded with a White House cabinet position, confirmed that thousands of records remain hidden, including: Epstein's original 2008 sex-trafficking indictment draft Search warrants from 2005 and 2019 raids Full lists of possible suspects and accomplices Witness statements and FBI and CIA files Autopsy and investigatory interviews into Epstein's death in prison The new release contains an April 2011 email from Epstein to Maxwell indicating that she misled the DOJ: she knew Trump had spent hours at Epstein's mansion with one of his victims. Epstein himself confirmed Trump's guilt, writing: "I have met some very bad people, none as bad as Trump." Epstein confirms that Trump knew about his pedophile ring. Of course he knew: That's why they were friends. The Epstein/Trump dump exposes Larry Summers, Clinton's Treasury Secretary and an economic adviser to Obama, decrying the MeToo movement in a private email to Epstein and making a sexist joke about women being stupid. Summers was the former president of Harvard University. Michael Wolff, media gossip profiteer and Trump whisperer, provided Epstein and sometimes Trump via Epstein with media consulting–in exchange for access to write his bestselling books. He was even Epstein's behind-the-scenes PR fixer during the Miami Herald investigations. Given that Epstein's victims have successfully sued banks for managing Epstein's human trafficking money, expect to see cases brought against Wolff. MAGA world is imploding. Trump huddled in the Situation Room with Pam Bondi, Kash Patel, and Lauren Boebert to stop the House vote. Boebert reportedly refused–likely because she faces a tough re-election campaign in a blue wave year. A new Democratic majority that finally includes Rep. Adelita Grijalva of Arizona will get their House vote to force the release of the full Epstein files. Once it passes the House, it still needs to clear 60 votes in the Senate. Trump is expected to veto it–after he and the MAGA disinformation machine ran on releasing the Epstein files, even accusing Biden of molesting his own daughter. For our bonus episode this week, we include the launch of Follow the Money, a new Gaslit Nation spinoff with Russian mafia expert Olga Lautman. In our first episode, we trace the Epstein-Trump financial nexus and expose the global corruption machine funding fascism. To listen, subscribe on YouTube, follow our new YouTube channel Follow the Money, and subscribe to Gaslit Nation on Patreon at the Truth-Teller level or higher. Every bit of support keeps us free to tell the truth, follow the money, and name the monsters. Thank you for making Gaslit Nation possible. Want to hear Gaslit Nation ad-free? Join our community of listeners for bonus shows, exclusive Q&A sessions, our group chat, invites to live events like our Monday political salons at 4pm ET over Zoom, and more! Sign up at Patreon.com/Gaslit! Show Notes: Subscribe to Andrea's new show with Russian mafia expert Olga Lautman: Follow the Money on YouTube: https://www.youtube.com/@FollowTheMoneyTrail   Lawrence: In newly public emails Epstein says 'of course' Trump 'knew about the girls' https://www.youtube.com/watch?v=Ik07YmrDJA4   In Matt Gaetz Scandal, Circumstances Left Teen Vulnerable to Exploitation A 17-year-old with a homeless parent wanted money for braces and ended up having sex for money with powerful men. She wants the public to have a fuller understanding of how she was victimized. https://www.nytimes.com/2025/11/13/us/politics/in-matt-gaetz-scandal-circumstances-left-girl-vulnerable-to-exploitation.html?unlocked_article_code=1.008.uayI.Sj1gT9qpKAZS&smid=url-share   Is Donald Trump Dying? JD Vance Seems to Think So https://gaslitnation.libsyn.com/is-donald-trump-dying-jd-vance-seems-to-think-so Fact Check: Posts Claim Contents of 'Ashley Biden's Diary' Have Been Verified. Here Are the Facts https://www.yahoo.com/news/fact-check-posts-claim-contents-181600349.html   https://x.com/yashar/status/1988623778146848967   https://x.com/matthewstoller/status/1988690518323429848   https://x.com/DavidShuster/status/1988728034426552451   https://x.com/jkbjournalist/status/1988747933047562503   https://x.com/allenanalysis/status/1988740115087159604   Ghislaine Maxwell told DOJ Trump never did anything concerning around her: Sources https://abcnews.go.com/US/trump-administration-considers-releasing-transcripts-doj-interview-ghislaine/story?id=124383957   This appears to be Epstein's response to @jkbjournalist.bsky.social 's Miami Herald report — www.miamiherald.com/news/local/a... — and involves a discussion with Michael Wolff about "plac[ing] a story." Wolff: "They've won the high ground—young, vulnerable, poor girls." https://bsky.app/profile/chrisgeidner.bsky.social/post/3m5hvne377s22   White House downplays new Epstein emails that mention Trump https://www.npr.org/2025/11/12/nx-s1-5605582/epstein-files-release-trump-email-grijalva-massie   Jeffrey Epstein claimed he gave Russians insight into Trump Newly released emails show the late convicted sex offender's extensive network of foreign contacts, whom he corresponded with about Trump's policy decisions. https://www.politico.com/news/2025/11/12/jeffrey-epstein-donald-trump-russia-emails-00648919?mod=djemCapitalJournalDaybreak   The DOJ says it won't release any more 'Epstein Files.' Here's what the government is still keeping secret. https://www.businessinsider.com/jeffrey-epstein-files-records-trump-admin-keeping-secret-may-release-2025-6   Perversion of Justice https://www.miamiherald.com/news/local/article238237729.html   Mimi Herald, New York Times seek to unseal records on Jeffrey Epstein's estate Read more at: https://www.miamiherald.com/news/local/article311986109.html   Lawsuits against banks with Epstein ties may shed new light on financier's crimes Experts say claim banks enabled Epstein will be difficult to prove but other outcomes could provide solace to victims https://www.theguardian.com/us-news/2025/oct/27/jeffrey-epstein-lawsuit-us-banks   Legal dispute with financiers of 'Top Gun: Maverick' casts spotlight on controversial Russian oligarch https://www.latimes.com/entertainment-arts/business/story/2023-01-03/top-gun-maverick-russian-oligarch-new-republic-pictures-dmitry-rybolovlev   When a trans woman first accused Jeffrey Epstein of rape, the media mocked her https://www.lgbtqnation.com/2025/07/when-a-trans-woman-first-accused-jeffrey-epstein-of-the-media-mocked-her/   Felon Freed by Trump Is Sentenced Again, This Time to 27 Months A Brooklyn federal judge found that Jonathan Braun had violated the rules of his release by assaulting a nanny, swinging an IV pole at a nurse and dodging tolls in luxury cars. https://www.nytimes.com/2025/11/10/nyregion/jonathan-braun-resentencing.html   The Characters in Paul Manafort's Career A supplement to The Atlantic's March issue cover story on Paul Manafort. https://www.theatlantic.com/membership/archive/2018/02/the-characters-in-paul-manaforts-career/552443/  

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.If you've ever watched a stock get crushed and thought, “Please let that not be my account,” this session is going to feel like a breath of fresh air. Today's AMA pulls straight from real viewer questions and breaks everything down in plain English. No fluff, no hype, just the stuff traders actually need to understand so they can save time, make money, and start winning with less risk.Right from the start, you'll hear about the new half ATR roll rule inside Plan M. This isn't theory. This came from thousands of backtested trades that revealed how rolling at the halfway point helps both winning and losing trades. It frees up capital, reduces stress, and keeps your account flexible without kicking you out of the position too soon. Once you understand how ATR behaves during a trade, the logic clicks instantly.Then we jump into implied volatility, extrinsic value, and how to avoid getting punished by wide bid ask spreads. It sounds complicated at first, but the way it's explained makes it surprisingly simple. You'll see why keeping extrinsic value under 30 percent is a core part of the approach, how deeper in the money options help control decay, and why implied volatility itself is never the enemy if you know how to adjust.There's also a recurring theme throughout the entire session. Trading is not about predicting the outcome. It is about following a tested plan and accepting risk with a clear mind. That idea comes to life when someone asks whether the current trade is good or bad. The answer is powerful. A trade is good when the rules are followed, not when the result happens to work out. That mindset shift is a game changer for anyone who has ever stressed over a red position.Here's a quick snapshot of what we walk through:✅ How Plan M's half ATR roll actually works✅ How implied volatility affects extrinsic value✅ Why the extrinsic percentage matters more than the IV number✅ How wide spreads can trigger bad stop losses✅ The four types of trades every trader must understandFrom there, things get even richer. We cover rolling calls and puts the right way, why covered calls in the money make no sense, whether inverse ETF calls are better than puts, and exactly how exit signals work across Plan M, Plan A, and Plan ETF. The order block section using OVTLYR's tools is especially helpful. If you've ever wondered why certain prices choke or bounce, you'll finally see what's happening behind the scenes.You'll also hear what five different Market Wizards taught over the years. The stories and lessons tie directly into the trading psychology at the heart of everything. Accepting uncertainty. Following a backtested plan. Removing expectation from any single trade. It all adds up to a calmer, more confident trading experience. And of course, the top five trading books are covered in detail so you can go deeper if you want to level up fast.If you're tired of second guessing yourself, or if you just want clarity on what actually works, this AMA is going to hit the spot. Think of it as sitting down with someone who's already lived through all the mistakes and is now showing you the shortcuts that actually matter.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Los hechos se registraron a 20 minutos de Popayán, zona donde delinque el frente Jaime Martínez de disidencias de ‘Iván Mordisco'.

In this episode, we talk calls about: a geologist breaking up and running into their ex, a caller wondering the age old question: What's a girl to do?, a pissbaby's ultimate revenge, someone asking how to do some malicious compliance as a sin, some nicknames in a relationship that seem weird, and a caller wants to know how to no longer be British. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 6:46 Geologist Break Up 15:12 What's a Girl to Do? 22:31 Pissbaby's Revenge 30:38 Malicious Compliance as a Sin 39:13 Boy Mom Nicknames 49:55 B Slur 1:00:01 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices

What does it take to deliver anesthesia in a hospital with no ventilator, scarce medication, and power that cuts out mid-surgery? Today we're joined by Dr. Mark Newton, pediatric anesthesiologist and longtime medical missionary, Mary Mungai, one of Kenya's first licensed nurse anesthetists and a leader in anesthesia education across East Africa; and Jackie Rowles, IFNA President and founder of Our Hearts Your Hands will take ​you ​far ​beyond ​the ​walls ​of ​the ​US ​Hospitals ​and ​surgery ​centers ​into ​low ​income ​countries ​where ​nurse ​anesthetists ​are ​delivering ​care ​under ​some ​of ​the ​most ​resource-limited ​and ​demanding ​conditions ​in ​the ​world.   Together, they share extraordinary stories of resilience, courage, and compassion — from training the first nurse anesthetists in Kenya to bringing safe anesthesia to war-torn regions like South Sudan and Somaliland. It's a look at how education, mentorship, and global partnerships are transforming access to safe surgical care — one provider, one patient, and one country at a time. Here's some of what you'll hear in this episode:

In this episode, we talk about: the horror that is the subreddit r/LinkedInLunatics, a listener who was stalked in the military, and we go over a TRUE Josh's best friend test in this week's circle jurdge This Episode is Brought to You By: Cozy Earth! Go to CozyEarth.com and use code JUDGIES to get up to 40% off your order Article! Go to Article.com/Judgies for $50 off your first purchase of $100 or more! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 4:44 Average Linkedin Profile 9:59 Take Your Shirt Off 16:06 CEO of Vimeo 18:51 Landlord Nick 21:20 Future Billionaire Child 24:04 Johnathon Deez Nutz 29:11 Adam J 32:10 Break 33:58 CJ: Best Friend Test 1:03:1 LS Sound 1:04:48 LS Story 1:13:49 Thicc 1:17:15 David E 1:19:46 Tom S 1:30:06 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices